| LUMERAN
Ranitidine
Description:
Lumeran
(Ranitidine) is a histamine H2-receptor antagonist.
It is several times potent than cimetidine on the basis of molecular
weight. It inhibits gastric acid secretion & the inhibition
is competitive & reversible. It inhibits both day time &
nocturnal basal gastric acid secretion stimulated by food.
Composition:
Lumeran-150
Tablet: Each film coated tablet containing Ranitidine hydrochloride
USP equivalent to 150 mg of ranitidine base.
Lumeran-300
Tablet: Each film coated tablet containing Ranitidine hydrochloride
USP equivalent to 300 mg of ranitidine base.
Indications:
• Treatment of
active duodenal ulcer.
• Benign gastric
ulcer.
• Treatment &
prevention of ulcer associated with non-steroidal anti-inflammatory
agent.
• Post operative
stress ulcer.
• Zollinger-Ellison
Syndrome.
• Gastroesophageal
reflux disease (GERD).
• Gastro-intestinal
haemorrhage from stress ulcer in seriously ill patient.
• Recurrent haemorrhage
in patients with bleeding peptic ulcer.
• Before general
anesthesia in patient considered to be at risk of acid aspiration
particulary obstetric patients.
Mode of Action:
Lumeran
(Ranitidine) is a specific, rapidly acting histamine H2
receptor-antagonist. It inhibits basal and stimulated secretion
of gastric acid both the volume & the acid & pepsin
content of secretion.
It has a relatively
long duration of action & so a single 150 mg & 300 mg
dose effectively suppresses gastric acid secretion for twelve
hours.
Absorption,
Fate & Excretion:
As a group, H2-antagonists
are rapidly well absorbed after oral administration; peak concentrations
in plasma are attained within 1 or 2 hours.
The half-life for
elimination of ranitidine is 2 to 3 hours. These drugs are in
large part excreted in the urine without being metabolized.
However, the half-life of ranitidine is significantly prolonged
in patients with hepatic dysfunction.
Dosage &
administration:
Adult : The usual
dose of Lumeran (Ranitidine) is 150 mg twice daily (in
the morning & at bed time) in the management of duodenal
& gastric ulcer a single daily dose of 300 mg at bed time
can be given as an alternative to twice daily administration
& treatment should be given initially for at least 4 weeks.
Where appropriate maintenance dose of 150 mg daily may be given
at bed time. In reflux oesophagitis the recommended dose is
150 mg twice daily or 300 mg at bed time for upto 8 weeks. In
pathological hypersecretory conditions, such as Zollinger-Ellison
Syndrome initial dose is usually 150 mg twice or thrice daily
& may be increased upto 6 g daily.
Side-effects:
Rarely dizziness,
insomnia, reversible mental confusion. Depression, diarrhoea,
nausea, vomiting, abdominal discomfort. Hallucination have been
reported, predominately in severely ill elderly patients. Hepatitis
anaphylactoid reaction, thrombocytopenia and leucopenia occur
rarely.
Precautions:
Since Lumeran
is excreted primarily by the kidney, dosage should be adjusted
in patients with impaired renal function. Caution should be
taken in patients with hepatic dysfunction. Symptomatic response
to Ranitidine therapy dose not preclude the presence of gastric
malignancy.
Drug Interactions:
Increased or decreased
prothrombin times have been reported during concurrent use of
Lumeran and warfarin. However, in human pharmacokinetics
studies with dosage of ranitidine upto 400 mg per day, no interaction
occurred, combined use of ranitidine and sucralfate should be
avoided because the later works best in acid medium. Absorption
of ketoconazole is decreased when used with Lumeran (Ranitidine).
Contraindications:
Patients hypersensitive
to Lumeran (Ranitidine).
Use in Pregnancy
and Lactation:
Safety of Lumeran
during pregnancy has not been established. This drug should
be used during pregnancy only if clearly needed. Ranitidine
is secreted in human milk, caution should be exercised when
it is administered to nursing mother.
Packing:
Lumeran-150
Tablet: Box containing 10 x 10's tablets in Alu-Alu pack.
Lumeran-300
Tablet: Box containing 5 x 10's tablets in strip pack. |
